<DOC>
	<DOCNO>NCT01023750</DOCNO>
	<brief_summary>Fenofibrate one best option treat hypertriglyceridemia . In majority patient , fenofibrate lower triglyceride ( TG ) 24-55 % improve HDL- LDL-cholesterol . However , response fenofibrate highly variable currently screen test identify poor responder . Genetic environmental factor may explain high variability response . Although exploratory nature , study clinical public health importance prediction drug response among hypertriglyceridemia clinically challenge fenofibrate prescription cost large ( $ 90 $ 130/patient/month ) ; target responsive patient outset help improve treatment outcome low cost . If successful , investigator propose conduct large , randomized trial effect pre-prescription genotyping fenofibrate response .</brief_summary>
	<brief_title>Predictors Response Fenofibrate</brief_title>
	<detailed_description />
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>19 year old dyslipidemic patient designate receive fenofibrate attend physician . All patient see UAB Diabetes Endocrine Clinic Cardiology Clinic . Women unable child surgery medical reason use effective form birth control study begin agree continue use effective form birth control 6 month take study drug . Under 19 and/or Dyslipidemic patient dyslipidemic medical condition ( e.g. , liver kidney disease ) warrant contraindication fenofibrate . Women pregnant , nursing woman , unless unable child surgery medical reason , use effective form birth control study begin and/or unwilling use effective form birth control 6 month take study drug exclude study .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>hypertriglyceridemia</keyword>
	<keyword>Triglycerides</keyword>
	<keyword>HDL</keyword>
	<keyword>Insulin resistance</keyword>
</DOC>